China SXT Pharmaceuticals Inc Announces Termination of Additional Purchase Right

China SXT Pharmaceuticals Inc. (NASDAQ: SXTC) announced it has terminated the additional purchase right previously granted to purchasers in its registered direct offering from October 8, 2026. This right, which allowed purchasers to buy up to an additional $12 million in shares or warrants, has been fully revoked. The termination does not impact the securities already issued in the initial offering, and all other terms of the original agreement remain in effect.